help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. 3, 320-329, March 2008; doi:10.1634/theoncologist.2007-0237
© 2008 AlphaMed Press

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 The Clinical Approach Towards Chondrosarcoma
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Google Scholar
Right arrow Articles by Gelderblom, H.
Right arrow Articles by Bovée, J. V.M.G.
PubMed
Right arrow Articles by Gelderblom, H.
Right arrow Articles by Bovée, J. V.M.G.

Sarcoma Research Series

The Clinical Approach Towards Chondrosarcoma

Hans Gelderbloma, Pancras C.W. Hogendoornb, Sander D. Dijkstrac, Carla S. van Rijswijkd, Augustinus D. Krola, Antonie H.M. Taminiauc, Judith V.M.G. Bovéeb

Departments of aClinical Oncology (Medical Oncology and Radiotherapy), bPathology, cOrthopedics, and dRadiology, Leiden University Medical Center, Leiden, The Netherlands

Key Words. Chondrosarcoma • Classification • Review • Mesenchymal chondrosarcoma • Radiotherapy • Chemotherapy

Correspondence: Hans Gelderblom, M.D., Ph.D., Department of Clinical Oncology, Leiden University Medical Center, P.O. Box 9600, Postzone K1-P, 2300RC Leiden, The Netherlands. Telephone: 31-(0)71-5263486; Fax: 31-(0)71-526670; e-mail: a.j.gelderblom{at}lumc.nl

Received December 3, 2007; accepted for publication January 28, 2008.

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.


   Learning Objectives
Top
 Footnotes
 Learning Objectives
Abstract
 Introduction
 Histopathological Classification...
 Radiological Presentation
 Surgical Treatment
 Radiotherapy
 Systemic Treatment
 Conclusion
 References
 
After completing this course, the reader will be able to:

  1. Classify the chondrosarcoma subtypes.
  2. Engage in the diagnostic process of chondrosarcoma.
  3. Evaluate the treatment options for chondrosarcoma.

Access and take the CME test online and receive 1 AMA PRA Category 1 CreditTM at CME.TheOncologist.com


   ABSTRACT
Top
 Footnotes
 Learning Objectives
 Abstract
Introduction
 Histopathological Classification...
 Radiological Presentation
 Surgical Treatment
 Radiotherapy
 Systemic Treatment
 Conclusion
 References
 
This review provides an overview of the histopathology, classification, diagnostic procedures, and therapy of skeletal chondrosarcoma. Chondrosarcomas that arise de novo are primary chondrosarcomas, whereas chondrosarcomas developing superimposed on pre-existing benign cartilage neoplasms such as enchondromas or osteochondromas are referred to as secondary chondrosarcomas. Conventional chondrosarcomas can be categorized according to their location in bone into central, peripheral, and juxtacortical chondrosarcomas. Histological grading is related to prognosis; however, it is also subject to interobserver variability. Rare subtypes of chondrosarcoma, including dedifferentiated, mesenchymal, and clear cell chondrosarcoma, are discussed as well. Magnetic resonance imaging is necessary to delineate the extent of the intraosseous and soft tissue involvement preoperatively. Computed tomography is especially recommended in the pelvis and other flat bones where it may be difficult to discern the pattern of bone destruction and the presence of matrix mineralization. Wide, en-bloc excision is the preferred surgical treatment in intermediate- and high-grade chondrosarcoma. In low-grade chondrosarcoma confined to the bone, extensive intralesional curettage followed by local adjuvant treatment and filling the cavity with bone graft has promising long-term clinical results and satisfactory local control. Chondrosarcomas are relatively radiotherapy resistant; therefore, doses >60 Gy are needed in attempts to achieve local control after incomplete resection. Irradiation with protons or other charged particles seems beneficial in this curative situation. Chemotherapy is only possibly effective in mesenchymal chondrosarcoma, and is of uncertain value in dedifferentiated chondrosarcoma. Potential new systemic treatment targets are being discussed.


   INTRODUCTION
Top
 Footnotes
 Learning Objectives
 Abstract
 Introduction
Histopathological Classification...
 Radiological Presentation
 Surgical Treatment
 Radiotherapy
 Systemic Treatment
 Conclusion
 References
 
Chondrosarcomas constitute a heterogeneous group of neoplasms that have the production of cartilage matrix by the tumor cells in common [1]. Chondrosarcoma is the third most common primary malignancy of bone after myeloma and osteosarcoma. The majority of these tumors grow slowly and rarely metastasize, and they have an excellent prognosis after adequate surgery. It is generally believed that, because of their extracellular matrix, low percentage of dividing cells, and poor vascularity, they are relatively chemo- and radiotherapy resistant. Wide surgical excision remains the best available treatment for intermediate- to high-grade tumors. However, a minority of patients present or recur with metastatic disease, and up to 13% of recurrent chondrosarcomas are of a higher grade than the original neoplasm [2, 3]. The clinical challenge is to prevent recurrence and to find better treatment options for unresectable or metastatic disease. The radiological and histopathological classification in relation to the clinical symptoms, medical history, and performance status is important for treatment decisions, which should be made by a team consisting of an experienced pathologist, radiologist, medical oncologist, radiotherapist, and orthopedic surgeon. An overview of the classification, clinical characteristics, and therapeutic options is provided in Table 1. New local and systemic treatment options are discussed. This multidisciplinary review addresses the most relevant issues concerning the diagnosis and treatment of chondrosarcoma and provides the current state of the art.


View this table:
[in this window]
[in a new window]

  		Table 1. Overview of clinical characteristics and therapeutic options in all subtypes of chondrosarcoma of bone

 

   HISTOPATHOLOGICAL CLASSIFICATION OF CHONDROSARCOMA
Top
 Footnotes
 Learning Objectives
 Abstract
 Introduction
 Histopathological Classification...
Radiological Presentation
 Surgical Treatment
 Radiotherapy
 Systemic Treatment
 Conclusion
 References
 
Conventional Chondrosarcoma
Conventional chondrosarcoma of bone constitutes approximately 85% of all chondrosarcomas. Conventional chondrosarcomas can be categorized according to their location in bone into primary central and secondary peripheral chondrosarcomas. The vast majority (>85%) are primary central chondrosarcomas, designated as such based on their location centrally within the medullar cavity. A minority (up to 15%) of conventional chondrosarcomas develop from the surface of bone, most of them as a result of malignant transformation within the cartilage cap of a pre-existing osteochondroma. These are therefore called secondary peripheral chondrosarcomas [4]. A minority (<1%) occur at the surface of bone, possibly of periosteal origin, and are designated periosteal chondrosarcoma. Their histology is similar to that of conventional chondrosarcoma. Juxtacortical chondrosarcoma should be distinguished from secondary peripheral chondrosarcoma because juxtacortical chondrosarcomas have a better prognosis, which is excellent after adequate local surgery alone [5–7].

Central and peripheral chondrosarcomas are histologically similar, and for both, three different grades are discerned, which is at present the best predictor of clinical behavior [3]. Grade I chondrosarcomas are lowly cellular, with an abundant hyaline cartilage matrix, and rarely metastasize [2]. In contrast, grade III chondrosarcomas are highly cellular, with a mucomyxoid matrix and mitoses, with metastases developing in 70% of patients [3] (Fig. 1). Up to 13% of recurrent chondrosarcomas exhibit a higher grade of malignancy than the original neoplasm [2, 3], suggesting chondrosarcomas may biologically progress. Moreover, recurrence of low-grade chondrosarcoma bears the risk for tumor progression toward a higher grade or even dedifferentiation, with a severe adverse prognosis.


Figure 1
View larger version (49K):
[in this window]
[in a new window]

  		Figure 1. Histology of grade I, II, and III chondrosarcoma. While cellularity is low in grade I chondrosarcoma (A) with chondroid matrix and absent mitoses, in grade II chondrosarcoma (B) mitoses are found (inset). In grade III chondrosarcoma (C), a high cellularity with muco-myxoid matrix changes is seen with cytonuclear atypia (hematoxylin and eosin staining, ~500x).

 
The distinction between benign (enchondroma or osteochondroma) and malignant (grade I chondrosarcoma) is, however, extremely difficult both at radiology [8] and histology [9], resulting in high interobserver variability [10]. Fortunately, with new treatment options using curettage and adjuvant phenol application or cryosurgery [11], as described below for enchondroma as well as grade I central chondrosarcoma, the distinction is not always essential for clinical decision making.

Histological grading is, however, also subject to interobserver variability [10]. This is worrisome, because therapy for grade I and grade II chondrosarcoma may differ, as discussed below. Therefore, there is an urgent need for molecular markers independent of histological grade that predict clinical behavior, which may guide clinical decision making. In addition, the elucidation of these markers may also reveal targets for future targeted therapy [12].

Central and peripheral chondrosarcomas differ at the molecular genetic level [13]. The exostosin (EXT) genes, causing multiple osteochondromas (MOs), are involved in the origin of osteochondroma and peripheral chondrosarcoma. In patients suffering hereditary MOs, germline mutations in EXT1 or EXT2 are found [14–16], combined with loss of the remaining wild-type allele in the cartilage cap of the osteochondroma [17]. In contrast, in solitary osteochondromas, EXT1 homozygous deletions are found in the tumor [18]. This results in decreased EXT expression in osteochondroma and secondary peripheral chondrosarcoma [19]. EXT is involved in heparan sulphate biosynthesis [20], and the resulting heparan sulphate proteoglycans (HSPGs) are important for cell signaling. In osteochondromas in which EXT is inactivated, the HSPGs seem to accumulate in the cytoplasm of the cell and Golgi apparatus, instead of being transported to be expressed at the cell surface [19]. This hampers growth signaling pathways, such as the Indian hedgehog (IHH)/parathyroid hormone–like hormone (PTHLH) protein, wingless type (Wnt) protein, and transforming growth factor (TGF)-β signaling pathways that are normally operative during skeletal growth. In peripheral chondrosarcoma, IHH signaling and Wnt signaling are downregulated and TGF-β signaling is upregulated upon increased histological grade. The exact trigger underlying malignant transformation of osteochondroma is unknown. Low-grade peripheral chondrosarcoma is near-haploid [21]. Moreover, PTHLH signaling, which is downstream of IHH and is responsible for chondrocyte proliferation, is absent in osteochondroma, while being upregulated upon malignant transformation [22, 23].

In contrast, in the far more common central chondrosarcoma, EXT is not involved, and the initiating event is still unknown. While enchondromas and low-grade chondrosarcomas are near-diploid and carry few karyotypic abnormalities, high-grade chondrosarcomas are aneuploid and have complex karyotypes [13, 24–26]. Some of the few consistent genetic aberrations include 12q13–15 and 9p21 rearrangements [13, 24, 26–29]. The CDKN2A (p16) tumor suppressor gene, located at 9p21, was shown to be important for chondrosarcoma progression [30, 31]. In addition, the progression from low-grade toward high-grade central chondrosarcoma is characterized by TP53 alterations [25]. Considering the IHH/PTHLH pathway, important in the normal growth plate, PTHLH signaling (PTHLH, parathyroid hormone receptor 1, and B-cell lymphoma 2 protein [BCL2]) was shown to be active in enchondromas as well as chondrosarcomas and increased with increasing histological grade, while IHH signaling was absent [22, 32–35].

Rare Chondrosarcoma Subtypes
In addition to conventional chondrosarcoma, several rare subtypes of chondrosarcoma are discerned, together constituting 10%–15% of all chondrosarcomas (Fig. 2).


Figure 2
View larger version (72K):
[in this window]
[in a new window]

  		Figure 2. Histology of rare chondrosarcoma subtypes. (A): Histology of dedifferentiated chondrosarcoma with a sharp interface between conventional chondrosarcoma (left) and anaplastic sarcoma (right). (B): Mesenchymal chondrosarcoma with undifferentiated small blue round cells (below) and cartilage differentiation (top). (C): Clear cell chondrosarcoma demonstrating chondrocytes with abundant clear cytoplasm, cartilaginous matrix, and deposition of osteoid. (hematoxylin and eosin staining, ~500x)

 
Dedifferentiated chondrosarcoma is a high-grade noncartilaginous sarcoma next to a (usually low-grade) malignant cartilage-forming tumor, with a remarkably sharp junction between the two components [36]. The tumor bears a dismal prognosis [37]. The rare genetic reports on dedifferentiated chondrosarcoma demonstrate that both components share identical genetic aberrations [38, 39], with additional genetic changes in the anaplastic component [38–41], indicating a common precursor cell with early diversion of the two components. No targets for therapy have been reported for dedifferentiated chondrosarcoma.

Mesenchymal chondrosarcoma is a highly malignant lesion that can occur in bone and soft tissue of relatively young patients and is characterized by varying amounts of differentiated cartilage admixed with undifferentiated small round cells [42]. A chromosomal abnormality der(13;21)(q10;q10) was found in two cases [43]. Although 61% of the tumors demonstrate p53 overexpression, no mutations were found [44]. In three cases, expression of the antiapoptotic BCL2, protein kinase C (PKC)-{alpha}, and platelet-derived growth factor receptor (PDGFR)-{alpha} pathways was found, suggesting targets for treatment, including interferon-{alpha} and ciprofloxacin inhibiting PKC-{alpha} activity or imatinib inhibiting PDGFR-{alpha} signaling [45].

Clear cell chondrosarcoma is a low-grade malignant tumor characterized by tumor cells with clear, empty cytoplasms. Metastases are rare, but may occur up to 24 years after initial diagnosis; thus, long term follow-up is mandatory [46]. A cytogenetic study on four cases suggested that extra copies of chromosome 20 and loss or rearrangements of 9p may be recurrent [47]. Expression of PTHLH, PDGF [48], IHH, Runt related transcription factor 2 [49], and matrix metalloproteinase 2 [50] was demonstrated, suggesting potential targets for future therapy.

It is generally debated whether true myxoid chondrosarcoma of bone exists. Although myxoid chondrosarcoma of bone has similar light microscopic features as extraskeletal myxoid "chondrosarcoma" (EMC), EMC is unrelated to skeletal high-grade (myxoid) chondrosarcoma of bone [51]. The original classification (EMC) as chondrosarcoma was based on positivity for S100, resemblance to chondroblasts on electron microscopy, and focal cartilage formation. Well-formed hyaline cartilage is, however, found in a minority of EMCs [52, 53]. In fact, expression of collagen II and aggrecan, two markers of cartilaginous differentiation, was absent in 86% of EMCs, while S100 expression was very focal or absent [53]. Therefore, the term "chondrosarcoma" in EMC is a misnomer and confusing. The 2002 World Health Organization classification classified this entity in the "tumors of uncertain differentiation" category. The translocation (9;22), which is specific for EMC, is generally absent in myxoid chondrosarcoma of bone and its ultrastructure is different [52]. The few reported cases of bone with proven t(9;22) have a large soft tissue component, which makes the distinction from EMC with bone destruction extremely difficult [54]. Thus, they represent two different entities, and myxoid chondrosarcoma of bone should be regarded as a myxoid variant of intermediate- or high-grade conventional chondrosarcoma.


   RADIOLOGICAL PRESENTATION
Top
 Footnotes
 Learning Objectives
 Abstract
 Introduction
 Histopathological Classification...
 Radiological Presentation
Surgical Treatment
 Radiotherapy
 Systemic Treatment
 Conclusion
 References
 
The distinction between benign and malignant cartilaginous lesions can be difficult. For the distinction between enchondroma and central grade I chondrosarcoma, conventional radiography is not reliable [8, 10, 55, 56]. Localization in the axial skeleton and size >5 cm have been shown to be reliable predictors for malignancy [8]. Dynamic contrast-enhanced magnetic resonance imaging (MRI) shows greater sensitivity [57, 58], although an absolute distinction between benign and malignant cannot be made on radiological grounds alone [8, 59, 60]. Regarding the differential diagnosis of osteochondroma versus low-grade peripheral chondrosarcoma, the thickness and staining characteristics on (dynamic) MRI of the cartilaginous cap provide a rather reliable assessment of the likelihood of malignancy [57].

The locations and radiographic appearances of the different chondrosarcoma subtypes are often characteristic [61], with the mineralized chondroid matrix as a punctate or ring-and-arc pattern of calcifications that may coalesce to form a more radiopaque flocculent pattern of calcification and aggressive features of endosteal scalloping and soft tissue extension. Low-grade chondrosarcoma is shown in Figure 3.


Figure 3
View larger version (88K):
[in this window]
[in a new window]

  		Figure 3. Radiological presentation of a conventional low-grade chondrosarcoma. (A): Conventional low-grade chondrosarcoma in the proximal humerus with chondroid mineralization on conventional radiograph. (B): Discrete endosteal scalloping of the anterior cortex is seen on the T1-weighted magnetic resonance image. (C): Axial T1-weighted magnetic resonance image with fat suppression after i.v. contrast injection demonstrates the typical peripheral ring-and-arc pattern of enhancement. No soft tissue extension is noted.

 
Aggressive chondrosarcoma subtypes, such as mesenchymal and dedifferentiated chondrosarcomas, often contain areas of matrix mineralization that suggest a chondroid neoplasm; however, they are relatively less extensive than conventional chondrosarcomas, and are usually ill-defined. They may demonstrate intraosseous lytic areas and show aggressive patterns of bone destruction with a moth-eaten to permeate pattern and large soft tissue masses.

Clear cell chondrosarcoma typically has a predilection for the proximal end of the femur and humerus, often with epiphyseal involvement. Radiographs reveal a predominantly lytic lesion. Matrix mineralization is not as frequently apparent in clear cell chondrosarcoma as in conventional chondrosarcoma.

Computed tomography (CT) and MRI are indispensable adjunct tools for optimizing tumor characterization [62]. CT is especially recommended in the pelvis and other flat bones where it may be difficult to discern the pattern of bone destruction and the presence of matrix mineralization. MRI is used to delineate the extent of intraosseous and soft tissue involvement. Evidence of a large unmineralized soft tissue mass associated with a lesion with radiological features indicative of a chondrosarcoma should raise the level of suspicion for dedifferentiation (Figs. 4 and 5).


Figure 4
View larger version (116K):
[in this window]
[in a new window]

  		Figure 4. Radiological presentation of a high-grade pelvic chondrosarcoma. (A): Axial T1-weighted magnetic resonance image of high-grade chondrosarcoma arising from the pelvis with cortex destruction and a large soft tissue component. (B): Axial T1-weighted magnetic resonance image with fat suppression after i.v. contrast injection shows areas of solid peripheral enhancement. (C): Computed tomography image demonstrates the bone destruction of the right os ilium and os sacrum with a large soft tissue mass with only peripheral mineralization.

 


Figure 5
View larger version (54K):
[in this window]
[in a new window]

  		Figure 5. Computed tomography image of mesenchymal chondrosarcoma arising from the posterior chest wall. The large tumor contains extensive areas of matrix mineralization. Aggressive lytic destruction of the posterior part of the rib and the thoracic vertebral body is noted. Histology of these lytic areas shows undifferentiated small round cells.

 

   SURGICAL TREATMENT
Top
 Footnotes
 Learning Objectives
 Abstract
 Introduction
 Histopathological Classification...
 Radiological Presentation
 Surgical Treatment
Radiotherapy
 Systemic Treatment
 Conclusion
 References
 
Although, for all grades and subtypes of nonmetastatic chondrosarcoma, complete surgical treatment offers the only chance for cure, the most optimal type of surgical management is still debated. Wide, en-bloc excision is the preferred surgical treatment of intermediate- and high-grade chondrosarcoma cases [63] (Fig. 6). However, wide excision can lead to considerable morbidity and a demanding reconstruction, depending on the location. On the other hand, in low-grade chondrosarcoma, extensive intralesional curettage followed by local adjuvant treatment, for example, phenolization or cryosurgery (liquid nitrogen), and filling the cavity with bone graft has promising long-term clinical results and satisfactory local control [11, 64]. Local adjuvant treatment can only be successfully used in lesions confined to the bone [64]. However, in some cases of low-grade chondrosarcoma, intralesional excision may not be adequate, for example, because of large size or an intra-articular or pelvic localization. In these cases, wide resection remains the preferable choice for local therapy. Metastases are rare in low-grade chondrosarcoma of the long bones [3]. In general, with current treatment strategies, including local adjuvant therapy, the local recurrence rate is low for grade I chondrosarcoma, but recurrence can occur >10 years postoperatively. In some reports, there were higher local recurrence rates with axial-pelvic tumors of all grades, with a greater tendency to metastasize and/or progress [65], while others were not able to confirm these associations [46, 63]. Local recurrence of a grade I chondrosarcoma in the long bones is associated with worse overall survival, compared with patients without local recurrence [66]. If the local recurrence is solitary, without progression in grade, and located in a long bone, the treatment of choice is an intralesional resection, again with local adjuvant therapy (Fig. 7). In the case of soft tissue involvement in chondrosarcoma grade I, we recommend wide en-bloc resection. Local recurrence of grade II or III chondrosarcoma located in the long and flat bones is treated with a wide excision, although it is often challenging to reach adequate wide resection margins in these patients. Grade I chondrosarcoma in flat bones should also be treated aggressively with a wide resection (Fig. 7).


Figure 6
View larger version (32K):
[in this window]
[in a new window]

  		Figure 6. Flowchart of the surgical management of central and peripheral chondrosarcoma.

 


Figure 7
View larger version (29K):
[in this window]
[in a new window]

  		Figure 7. Flowchart of the surgical management of local recurrence in central chondrosarcoma.

 
In patients with MOs, the development of secondary peripheral chondrosarcoma is rare (assumed in the literature to be <2%) and usually presents after skeletal maturity. Complete surgical removal of the cartilage cap with the pseudocapsule has excellent long-term clinical and local results (Fig. 6). The most common location is the pelvis, where the large cartilage cap can be difficult to excise. In a series of 61 patients with grade I or II secondary peripheral chondrosarcoma of the pelvis published by Donati et al. [67], a 3% local recurrence rate was found after wide resection, in contrast with 23% after inadequate excision.

In our experience, for patients presenting with unresectable lesions of mucoid consistency (usually grade II or III conventional chondrosarcoma), tumor suction is a palliative option for tumor-related pain.

The prognosis for patients with dedifferentiated chondrosarcoma is still poor, despite adequate wide surgical resection and adjuvant systemic therapy. In the case of a pathological fracture of the long bones, wide excision with adequate reconstruction is preferable.


   RADIOTHERAPY
Top
 Footnotes
 Learning Objectives
 Abstract
 Introduction
 Histopathological Classification...
 Radiological Presentation
 Surgical Treatment
 Radiotherapy
Systemic Treatment
 Conclusion
 References
 
As chondrosarcomas grow slowly, with a relatively low fraction of dividing cells, and radiotherapy (RT) acts at dividing cells, chondrogenic tumors are considered relatively RT resistant. RT can be considered in two situations: after incomplete resection, aiming at maximal local control (curative), and in situations where resection is not feasible or would cause unacceptable morbidity (palliative). For curative intentions, doses >60 Gy are required to achieve local control. However, application of this dose with conventional high-energy photon RT is often impossible in the vicinity of critical (neurological) structures, especially in chondrosarcomas arising in the skull base and axial skeleton. Unfortunately, in this situation, postoperative RT is often indicated because these tumors are less accessible for radical resection than lesions in the appendicular skeleton. Given the limitations of conventional RT with photons, alternative radiation modalities have been tested.

Particle therapy with protons has the advantage of a minimal exit dose after energy deposition in the target volume, and hence better sparing of critical structures close to the tumor. Proton RT has been found to be beneficial in incompletely resected chondrogenic tumors of the skull base and axial skeleton. Local control rates of 85%–100% with mixed photon–proton or proton-only protocols (doses up to 79 cobalt Gray equivalents) have been reported by several authors [68–71], with limited severe late effects (<10% incidence of Radiation Therapy Oncology Group [RTOG] grade 3 toxicity). RT with carbon ions or other charged particles represents another attractive radiation modality, which combines the physical advantages of protons with a higher radiobiological activity. Shulz-Ertner et al. [72] recently reported on the effectiveness and toxicity of carbon ion RT in chondrosarcomas of the skull base treated between 1998 and 2005 in Heidelberg. All 54 patients had gross residual disease after surgery. With a median follow-up of 33 months, the actuarial local control rates were 96% and 90% at 3 and 4 years, respectively. RTOG grade 3 late toxicity was lower than with proton RT. Results of RT with helium and neon ions were reported by Castro et al. [73], with a 5-year local control rate of 78%.

Chondrosarcomas that are not resectable and cause complaints might be considered for palliative RT, especially mesenchymal chondrosarcomas, because these tumors are more radiosensitive, in our experience. Limited evidence from older series suggests benefit from conventional RT for chondrosarcomas that cannot be resected. McNaney et al. [74] reviewed the MD Anderson experience with chondrosarcoma in 20 patients. Five of 11 patients treated with RT as monotherapy were controlled with doses of 40–70 Gy; the median follow-up was 53 months. Data on primary RT for chondrosarcomas from Princess Margaret Hospital in Toronto, Canada [75], support the observation that conventional RT can sometimes provide local control and symptom relief.


   SYSTEMIC TREATMENT
Top
 Footnotes
 Learning Objectives
 Abstract
 Introduction
 Histopathological Classification...
 Radiological Presentation
 Surgical Treatment
 Radiotherapy
 Systemic Treatment
Conclusion
 References
 
Chemotherapy is generally not effective in chondrosarcoma, especially in the most frequently observed conventional type and the rare (low-grade) clear cell variant. An additional explanation for this chemotherapy resistance may be expression of the multidrug-resistance 1 gene, P-glycoprotein, resulting in resistance to doxorubicin in vitro [76]. Moreover, the access of anticancer agents may be hampered by the large amount of extracellular matrix and the poor vascularity, implying that the agents have to diffuse over a relatively long distance in order to reach the tumor cells. Moreover, chondrosarcoma grows relatively slowly, while most conventional chemotherapeutic agents act at actively dividing cells. The effect of chemotherapy on grade II and III chondrosarcoma is difficult to assess because the number of reported cases is too low and reported series are mostly retrospective, which may lead to selection bias. There is an urgent need for inclusion of these patients in prospective trials.

Because of a lack of clear evidence, the role of adjuvant chemotherapy in dedifferentiated chondrosarcoma remains unclear, and the standard use of adjuvant chemotherapy outside a clinical protocol should be reconsidered. One study seemed to show an effect on survival [77], which was not confirmed by others [37, 78, 79]. For peripheral dedifferentiated chondrosarcoma, arising in osteochondroma, chemotherapy led to longer survival in a small retrospective report [80]. In a small prospective study of doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of bone, both patients with dedifferentiated chondrosarcoma had a poor response in their primary tumor, although two of four patients had a complete response of metastases [81].

For mesenchymal chondrosarcoma, there seems to be a role for chemotherapy, although the number of reported cases is even smaller. Huvos et al. [82] published a retrospective series of patients with mesenchymal chondrosarcoma treated with preoperative chemotherapy showing three complete and three partial responses (all T-10 or T-11 protocols) and three nonresponders (all high-dose methotrexate monotherapy) of nine patients treated with preoperative chemotherapy. Nooij et al. [81] prospectively observed one of two good pathological responses in the primary tumor after preoperative doxorubicin–cisplatin combination therapy, but only a limited effect in four patients treated with the same regimen in the metastatic setting (two with stable diseases). Several other publications report cases sensitive to radiochemotherapy [83, 84]. Tumors with a high percentage of small cells and limited cartilage content are thought to be most sensitive to chemotherapy and RT [82], as with other small cell sarcomas. Although prospective studies are lacking, mesenchymal chondrosarcomas are considered sensitive to doxorubicin-based combination chemotherapy as used in other bone tumors. Thus, patients with mesenchymal chondrosarcoma should be considered for adjuvant chemotherapy, and in the case of metastatic disease, palliative chemotherapy.

Additional potential targets for systemic therapy for the different chondrosarcoma subtypes are shown in Table 1 and were extensively reviewed in 2005 [12]. More recently, the antitumor effects of histone deacetylase and aromatase inhibitors were described in chondrosarcoma cell lines, and angiogenesis inhibitors were described in an in vivo model [85–87]. Several phase I studies have reported incidental responses of chondrosarcomas to newer targeted agents, such as vascular endothelial growth factor antisense [88] and recombinant human Apo2L/tumor necrosis factor receptor apoptosis-inducing ligand (TRAIL) [89]. Current phase II trials open for chondrosarcoma patients are using the following drugs: perifosine (serine/threonine kinase Akt inhibitor), apomab (proapoptotic selective agonist of Apo2L/TRAIL death receptor), dasatinib (multitargeted small-molecule tyrosine kinase inhibitor), and the combination of gemcitabine and docetaxel [90]. Also, patients with dedifferentiated chondrosarcomas are allowed in the Euroboss adjuvant trial of the Scandinavian Sarcoma Group [91].


   CONCLUSION
Top
 Footnotes
 Learning Objectives
 Abstract
 Introduction
 Histopathological Classification...
 Radiological Presentation
 Surgical Treatment
 Radiotherapy
 Systemic Treatment
 Conclusion
References
 
Chondrosarcoma of bone generally has a good prognosis when optimally diagnosed and treated by an experienced team of specialists. Experienced assessment of histological grade and adequate histopathological and radiological (conventional x-ray, MRI, and in some cases CT) classification is used to guide treatment decisions. For conventional low-grade chondrosarcoma confined to the bone, intralesional curettage with local adjuvant therapy (phenol application or cryosurgery) is an option to decrease surgical morbidity. In intermediate- to high-grade tumors, clear margins are necessary to prevent recurrence. It is obvious that recurrences should be avoided, and when they occur they should be treated adequately, especially because they might be of higher histological grade, increasing the risk for metastases and a fatal outcome. Chondrosarcomas are relatively RT resistant; therefore, doses >60 Gy are needed for maximal local control after incomplete resection. Because this high-dose RT is often not feasible with conventional photons, new techniques, such as the use of protons or charged particles, have been tested, with promising results. Chemotherapy is only possibly effective in mesenchymal chondrosarcoma, and is of uncertain value in dedifferentiated chondrosarcoma; both subtypes are rare and bear a poor prognosis. Chemotherapy should preferably be used in clinical trials to define its definite role in chondrosarcoma. Several new drug targets have been identified and phase II studies are currently ongoing. There is an urgent need for new standard systemic treatment options for the minority of patients with unresectable or metastatic disease.


   FOOTNOTES
 
Conception/design: Hans Gelderblom

Manuscript writing: Hans Gelderblom, Pancras C.W. Hogendoorn, Sander D. Dijkstra, Carla S. van Rijswijk, Augustinus D. Krol, Antonie H.M. Taminiau, Judith V.M.G. Bovée

Final approval of manuscript: Hans Gelderblom, Pancras C.W. Hogendoorn, Sander D. Dijkstra, Carla S. van Rijswijk, Augustinus D. Krol, Antonie H.M. Taminiau, Judith V.M.G. Bovée


   REFERENCES
Top
 Footnotes
 Learning Objectives
 Abstract
 Introduction
 Histopathological Classification...
 Radiological Presentation
 Surgical Treatment
 Radiotherapy
 Systemic Treatment
 Conclusion
 References
 

  1. World Health Organization, Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone. Cartilage tumours. Lyon, France: IARC Press, 2002:234-257.
  2. Bjornsson J, McLeod RA, Unni KK et al. Primary chondrosarcoma of long bones and limb girdles. Cancer 1998;83:2105–2119.[CrossRef][Medline]
  3. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977;40:818–831.[CrossRef][Medline]
  4. Bertoni F, Bacchini P, Hogendoorn PCW. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Chondrosarcoma. Lyon, France: IARC Press, 2002:247-251.
  5. Vanel D, De Paolis M, Monti C et al. Radiological features of 24 periosteal chondrosarcomas. Skeletal Radiol 2001;30:208–212.[CrossRef][Medline]
  6. Schajowicz F, Sobin LH, World Health Organization. Histological Typing of Bone Tumours, International Histological Classification of Tumours. Second Edition. Berlin: Springer-Verlag, 1993:249-282.
  7. Schajowicz F. Juxtacortical chondrosarcoma. J Bone Joint Surg Br 1977;59-B:473–480.[Medline]
  8. Geirnaerdt MJA, Hermans J, Bloem JL et al. Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma. AJR Am J Roentgenol 1997;169:1097–1104.[Abstract/Free Full Text]
  9. Mirra JM, Gold R, Downs J et al. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res 1985;(201):214–237.
  10. Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J Bone Joint Surg Am 2007;89:2113–2123.[Abstract/Free Full Text]
  11. Veth R, Schreuder B, van Beem H et al. Cryosurgery in aggressive, benign, and low-grade malignant bone tumours. Lancet Oncol 2005;6:25–34.[Medline]
  12. Bovée JVMG, Cleton-Jansen AM, Taminiau AHM et al. Emerging pathways in the development of chondrosarcoma of bone and the implications for targeted treatment. Lancet Oncol 2005;6:599–607.[CrossRef][Medline]
  13. Bovée JVMG, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer 1999;26:237–246.[CrossRef][Medline]
  14. Ahn J, Ludecke H-J, Lindow S et al. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet 1995;11:137–143.[CrossRef][Medline]
  15. Stickens D, Clines G, Burbee D et al. The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet 1996;14:25–32.[CrossRef][Medline]
  16. Wuyts W, Van Hul W, Wauters J et al. Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet 1996;5:1547–1557.[Abstract/Free Full Text]
  17. Bovée JVMG, Cleton-Jansen AM, Wuyts W et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 1999;65:689–698.[CrossRef][Medline]
  18. Hameetman L, Szuhai K, Yavas A et al. The role of EXT1 in nonhereditary osteochondroma: Identification of homozygous deletions. J Natl Cancer Inst 2007;99:396–406.[Abstract/Free Full Text]
  19. Hameetman L, David G, Yavas A et al. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol 2007;211:399–409.[CrossRef][Medline]
  20. McCormick C, Leduc Y, Martindale D et al. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 1998;19:158–161.[CrossRef][Medline]
  21. Bovée JVMG, van Royen M, Bardoel AFJ et al. Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma. Am J Pathol 2000;157:1587–1595.[Abstract/Free Full Text]
  22. Bovée JVMG, van den Broek LJCM, Cleton-Jansen AM et al. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000;80:1925–1934.[Medline]
  23. Hameetman L, Kok P, Eilers PHC et al. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 2005;446:430–437.[CrossRef][Medline]
  24. Tallini G, Dorfman H, Brys P et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol 2002;196:194–203.[CrossRef][Medline]
  25. Rozeman LB, Hogendoorn PCW, Bovée JVMG. Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn 2002;2:461–472.[CrossRef][Medline]
  26. Rozeman LB, Szuhai K, Schrage YM et al. Array-comparative genomic hybridization of central chondrosarcoma: Identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations. Cancer 2006;107:380–388.[CrossRef][Medline]
  27. Sandberg AA. Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 2004;16:342–354.[CrossRef][Medline]
  28. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet 2003;143:1–31.[CrossRef][Medline]
  29. Larramendy ML, Tarkkanen M, Valle J et al. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 1997;150:685–691.[Abstract]
  30. van Beerendonk HM, Rozeman LB, Taminiau AHM et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: Indication of an important gene for tumour progression. J Pathol 2004;202:359–366.[CrossRef][Medline]
  31. Asp J, Sangiorgi L, Inerot SE et al. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. Int J Cancer 2000;85:782–786.[CrossRef][Medline]
  32. Rozeman LB, Hameetman L, Cleton-Jansen AM et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol 2005;205:476–482.[CrossRef][Medline]
  33. Amling M, Posl M, Hentz MW et al. PTHrP and Bcl-2: Essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors. Verh Dtsch Ges Pathol 1998;82:160–169.[Medline]
  34. Kunisada T, Moseley JM, Slavin JL et al. Co-expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in cartilaginous tumours: A marker for malignancy? Pathology 2002;34:133–137.[CrossRef][Medline]
  35. Pateder DB, Gish MW, O'Keefe RJ et al. Parathyroid hormone-related peptide expression in cartilaginous tumors. Clin Orthop Relat Res 2002;(403):198–204.
  36. Milchgrub S, Hogendoorn PCW. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone. Dedifferentiated chondrosarcoma. Lyon, France: IARC Press, 2002:252-254.
  37. Grimer RJ, Gosheger G, Taminiau A et al. Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group. Eur J Cancer 2007;43:2060–2065.[CrossRef][Medline]
  38. Bovée JVMG, Cleton-Jansen AM, Rosenberg C et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 1999;189:454–462.[CrossRef][Medline]
  39. Ropke M, Boltze C, Neumann HW et al. Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. Pathol Res Pract 2003;199:437–444.[CrossRef][Medline]
  40. Grote HJ, Schneider-Stock R, Neumann W et al. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma. Virchows Arch 2000;436:494–497.[CrossRef][Medline]
  41. Coughlan B, Feliz A, Ishida T et al. p53 Expression and DNA ploidy of cartilage lesions. Hum Pathol 1995;26:620–624.[CrossRef][Medline]
  42. Nakashima Y, Park YK, Sugano O. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone. Mesenchymal chondrosarcoma. Lyon, France: IARC Press, 2002:255-256.
  43. Naumann S, Krallman PA, Unni KK et al. Translocation der(13;21)(q10;q10) in skeletal and extraskeletal mesenchymal chondrosarcoma. Mod Pathol 2002;15:572–576.[CrossRef][Medline]
  44. Park YK, Park HR, Chi SG et al. Overexpression of p53 and rare genetic mutation in mesenchymal chondrosarcoma. Oncol Rep 2000;7:1041–1047.[Medline]
  45. Brown RE, Boyle JL. Mesenchymal chondrosarcoma: Molecular characterization by a proteomic approach, with morphogenic and therapeutic implications. Ann Clin Lab Sci 2003;33:131–141.[Abstract/Free Full Text]
  46. Donati D, Yin JQ, Colangeli M et al. Clear cell chondrosarcoma of bone: Long time follow-up of 18 cases. Arch Orthop Trauma Surg 2008;128:137–142.[CrossRef][Medline]
  47. Nishio J, Reith JD, Ogose A et al. Cytogenetic findings in clear cell chondrosarcoma. Cancer Genet Cytogenet 2005;162:74–77.[CrossRef][Medline]
  48. Masui F, Ushigome S, Fujii K. Clear cell chondrosarcoma: A pathological and immunohistochemical study. Histopathology 1999;34:447–452.[CrossRef][Medline]
  49. Park HR, Park YK. Differential expression of runx2 and Indian hedgehog in cartilaginous tumors. Pathol Oncol Res 2007;13:32–37.[Medline]
  50. Corradi D, Bacchini P, Campanini N et al. Aggressive clear cell chondrosarcomas: Do distinctive characteristics exist? A report of 4 cases. Arch Pathol Lab Med 2006;130:1673–1679.[Medline]
  51. Goh YW, Spagnolo DV, Platten M et al. Extraskeletal myxoid chondrosarcoma: A light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology 2001;39:514–524.[CrossRef][Medline]
  52. Antonescu CR, Argani P, Erlandson RA et al. Skeletal and extraskeletal myxoid chondrosarcoma: A comparative clinicopathologic, ultrastructural, and molecular study. Cancer 1998;83:1504–1521.[CrossRef][Medline]
  53. Aigner T, Oliveira AM, Nascimento AG. Extraskeletal myxoid chondrosarcomas do not show a chondrocytic phenotype. Mod Pathol 2004;17:214–221.[CrossRef][Medline]
  54. Kilpatrick SE, Inwards CY, Fletcher CD et al. Myxoid chondrosarcoma (chordoid sarcoma) of bone: A report of two cases and review of the literature. Cancer 1997;79:1903–1910.[CrossRef][Medline]
  55. Sanerkin NG. The diagnosis and grading of chondrosarcoma of bone: A combined cytologic and histologic approach. Cancer 1980;45:582–594.[CrossRef][Medline]
  56. Schiller AL. Diagnosis of borderline cartilage lesions of bone. Semin Diagn Pathol 1985;2:42–62.[Medline]
  57. Geirnaerdt MJA, Bloem JL, Eulderink F et al. Cartilaginous tumors: Correlation of gadolinium-enhanced MR imaging and histopathologic findings. Radiology 1993;186:813–817.[Abstract]
  58. Geirnaerdt MJ, Hogendoorn PCW, Bloem JL et al. Cartilaginous tumors: Fast contrast-enhanced MR imaging. Radiology 2000;214:539–546.[Abstract/Free Full Text]
  59. Hudson TM, Manaster BJ, Springfield DS et al. Radiology of medullary chondrosarcoma: Preoperative treatment planning. Skeletal Radiol 1983;10:69–78.[CrossRef][Medline]
  60. Dietlein M, Féaux de Lacroix W, Neufang KFR et al. [Assessment of the grading of cartilaginous tumors of the long tubular bones from the radiologic and pathologic viewpoint.]. Rontgenblatter 1990;174:180; German.
  61. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press, 2002:247-258.
  62. Littrell LA, Wenger DE, Wold LE et al. Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas: A retrospective review of 174 de novo cases. Radiographics 2004;24:1397–1409.[Abstract/Free Full Text]
  63. Fiorenza F, Abudu A, Grimer RJ et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002;84:93–99.[CrossRef][Medline]
  64. Leerapun T, Hugate RR, Inwards CY et al. Surgical management of conventional grade I chondrosarcoma of long bones. Clin Orthop Relat Res 2007;(463):166–172.
  65. Weber KL, Pring ME, Sim FH. Treatment and outcome of recurrent pelvic chondrosarcoma. Clin Orthop Relat Res 2002;(397):19–28.
  66. Schwab JH, Wenger D, Unni K et al. Does local recurrence impact survival in low-grade chondrosarcoma of the long bones? Clin Orthop Relat Res 2007;(462):175–180.
  67. Donati D, El Ghoneimy A, Bertoni F et al. Surgical treatment and outcome of conventional pelvic chondrosarcoma. J Bone Joint Surg Br 2005;87:1527–1530.[CrossRef][Medline]
  68. Noel G, Habrand JL, Jauffret E et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 2003;179:241–248.[CrossRef][Medline]
  69. Hug EB, Loredo LN, Slater JD et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999;91:432–439.[Medline]
  70. Weber DC, Rutz HP, Pedroni ES et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: The Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys 2005;63:401–409.[CrossRef][Medline]
  71. Rosenberg AE, Nielsen GP, Keel SB et al. Chondrosarcoma of the base of the skull. A clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 1999;23:1370–1378.[CrossRef][Medline]
  72. Schulz-Ertner D, Nikoghosyan A, Hof H et al. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys 2007;67:171–177.[Medline]
  73. Castro JR, Linstadt DE, Bahary JP et al. Experience in charged particle irradiation of tumors of the skull base: 1977–1992. Int J Radiat Oncol Biol Phys 1994;29:647–655.[Medline]
  74. McNaney D, Lindberg RD, Ayala AG et al. Fifteen year radiotherapy experience with chondrosarcoma of bone. Int J Radiat Oncol Biol Phys 1982;8:187–190.[Medline]
  75. Krochak R, Harwood AR, Cummings BJ et al. Results of radical radiation for chondrosarcoma of bone. Radiother Oncol 1983;1:109–115.[Medline]
  76. Wyman JJ, Hornstein AM, Meitner PA et al. Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: Expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J Orthop Res 1999;17:935–940.[CrossRef][Medline]
  77. Mitchell AD, Ayoub K, Mangham DC et al. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br 2000;82:55–61.[CrossRef][Medline]
  78. Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer 2006;106:2682–2691.[CrossRef][Medline]
  79. Dickey ID, Rose PS, Fuchs B et al. Dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes. J Bone Joint Surg Am 2004;86-A:2412–2418.[Abstract/Free Full Text]
  80. Staals EL, Bacchini P, Mercuri M et al. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am 2007;89:987–993.[Abstract/Free Full Text]
  81. Nooij MA, Whelan J, Bramwell VH et al. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: A European Osteosarcoma Intergroup Study. Eur J Cancer 2005;41:225–230.[CrossRef][Medline]
  82. Huvos AG, Rosen G, Dabska M et al. Mesenchymal chondrosarcoma. A clinicopathologic analysis of 35 patients with emphasis on treatment. Cancer 1983;51:1230–1237.[CrossRef][Medline]
  83. Harwood AR, Krajbich JI, Fornasier VL. Mesenchymal chondrosarcoma: A report of 17 cases. Clin Orthop Relat Res 1981;(158):144–148.
  84. Sevel D. Mesenchymal chondrosarcoma of orbit. Br J Ophthalmol 1974;58:882–887.[Free Full Text]
  85. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ et al. Estrogen signaling is active in cartilaginous tumors: Implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005;11:8028–8035.[Abstract/Free Full Text]
  86. Sakimura R, Tanaka K, Yamamoto S et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 2007;13:275–282.[Abstract/Free Full Text]
  87. Klenke FM, Abdollahi A, Bertl E et al. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 2007;7:49.[CrossRef][Medline]
  88. Levine AM, Tulpule A, Quinn DI et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006;24:1712–1719.[Abstract/Free Full Text]
  89. Herbst RS, Mendolson DS, Ebbinghaus S et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 2006;24(suppl 18, Abstract 3013.
  90. Available at http://www.clinicaltrials.gov/ct2/results?cond=%22Chondrosarcoma%22. Accessed November 19, 2007.
  91. Scandinavian Sarcoma Group and Oncologic Center, Lund, Sweden. Euroboss I: A European Treatment Protocol for Bone Sarcoma in Patients Older Than 40 Years. Available at http://www.radium.no/sarcoma/FTP/pdf/Euroboss1.pdf. Accessed February 24, 2008.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 The Clinical Approach Towards Chondrosarcoma
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Google Scholar
Right arrow Articles by Gelderblom, H.
Right arrow Articles by Bovée, J. V.M.G.
PubMed
Right arrow Articles by Gelderblom, H.